anlon

August 13, 2026

To,	To,
Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	**The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL**

Sub: Intimation with respect to our earlier intimation dated August 08, 2026 under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("SEBI Listing Regulations")

Respected Sir/Madam,

Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations, and with reference to our earlier intimation dated August 08, 2026 we hereby submit revised intimation to clarify that the percentage of acquisition was inadvertently mentioned as 32.52% instead of 44.94% in Apiqo Organics Private Limited ("AOPL") and 43.33% instead of 47.41% in of Bizotic Lifescience Private Limited ("BLPL") in the earlier intimation.

The correct percentage of acquisition is 44.94% in Apiqo Organics Private Limited ("AOPL") and 47.41% in of Bizotic Lifescience Private Limited ("BLPL"). Accordingly, wherever 32.52% is mentioned in the earlier intimation, the same may kindly be read as 44.94% for Apiqo Organics Private Limited ("AOPL") and 47.41% in case of Bizotic Lifescience Private Limited ("BLPL").

All other details and disclosures contained in the earlier intimation remain unchanged.

We regret the inadvertent error and request you to take the above revised disclosure on record.

The Annexures herein contains details pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the Listing Regulations by listed entities, bearing ref. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

You are requested to take the above information on your record.

Thanking You.
For ANLON HEALTHCARE LIMITED

Rasadia
Punitkumar
Rameshbhai

Digitally signed by Rasadia Punitkumar Rameshbhai
DN: c=IN, o=Personal, title=4798,
pseudonym=13363440366292472861WAue1dglYlP1,
2.5.4.20=a003a5c41c134976122eef293c4077137aa4a1ecd74ed223ac0e8dcc8264a5a2, postalCode=360005,
st=Gujarat,
serialNumber=9067d666c809e74b4abe895e7d3c841cee4ae962d432d246758d2cb6b96167f3, cn=Rasadia Punitkumar Rameshbhai
Date: 2026.08.13 13:03:26 +05'30'

PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258

ANNEXURE-A

Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Apiqo Organics Private Limited ("AOPL") (CIN: U21001GJ2025PTC169863) is an Indian private limited company, incorporated on December 1, 2025, by way of conversion from the partnership firm to a private limited company. Brief details: AOPL is *inter alia* engaged in manufacturing pharmaceutical intermediate, industrial and fine chemicals and inorganic chemicals, Turnover: Rs.7,254.11/- Lakh (as on 31.03.2026) and Rs.4,554.36/- Lakh (as on 30.06.2026)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition qualifies as a Related Party Transaction under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and some of the directors are common in both entities. The promoter(s), promoter group or group companies have interest in the entity whose shareholding is proposed to be acquired. The transaction is being undertaken pursuant to the terms and conditions of the AOPL SSA executed between the parties and is on an arm's length basis.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of further shares of AOPL is made with an objective to strengthen the supply of critical materials for the Company, achieve strategic synergies, and enhance long-term shareholder value.

5	Brief details of any governmental or regulatory approvals required for the acquisition;	In principle, listing and trading approval of the stock exchanges shall be required for listing of the shares to be issued pursuant to preferential issue.
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain customary closing conditions under the AOPL SSA and is expected to be completed within 90 days from the date of signing of the AOPL SSA or by such other timelines as may be mutually agreed between the parties
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The transaction is proposed to be effected through a share swap agreement pursuant to which equity shares of the Company shall be issued and allotted to the shareholders of AOPL, in consideration for acquisition of their equity shares held in AOPL, subject to applicable laws and approvals. No cash consideration is expected to be payable.
8	Cost of acquisition and/or the price at which the shares are acquired;	The consideration shall be discharged by issuance of equity shares of the Company in accordance with the agreed share exchange ratio/ swap ratio. The aggregate consideration is approximately Rs. 1,165,179,600/-, subject to customary adjustments, if any. Cost of acquisition: Rs. 1,165,179,600/- Price at which shares are acquired: Up to 45,16,200 equity shares at price of Rs.258/- each aggregating Rs. 1,165,179,600/-.
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Percentage of shareholding acquired: The Company expects to acquire up to 44.94% shareholding in AOPL, subject to acceptance of share swap proposal by all the shareholders of AOPL.

<table>
<tr><td></td><td></td><td><u>Control acquired</u>: Not applicable pursuant to the proposed transaction.

<u>Number of shares acquired</u>: Up to 45,16,200 equity shares of the Target Company.</td></tr>
<tr><td>10</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</td><td><u>Brief background</u>: Please refer (1) above.

<u>Country in which the acquired entity has presence</u>: India

<u>Turnover for the last 3 years</u>:

<table><tr><td>Financial Year</td><td>Amt. in Lakh</td></tr><tr><td>2023-24</td><td>Rs.1,711.10</td></tr><tr><td>2024-25</td><td>Rs.977.78</td></tr><tr><td>2025-26</td><td>Rs.7,254.11</td></tr></table></td></tr>
</table>

ANLON HEALTHCARE LIMITED
CIN No.: U24230GJ2013PLC077543
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)
PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

ANNEXURE-B
Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Bizotic Lifescience Private Limited ("BLPL") (CIN: U33111GJ2015PTC082917) is an Indian private limited company, incorporated on April 17, 2015. Brief details: BLPL is *inter alia* engaged in the business of manufacturing, supplying and exporting pharmaceutical drugs and intermediates, industrial and fine chemicals, more specifically, active pharmaceutical ingredients (API) including providing contract research and manufacturing services. Turnover: Rs.3,126.64/- Lakh (as on 31.03.2026) and Rs.1152.78/- Lakh (as on 30.06.2026)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition qualifies as a Related Party Transaction under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as promoters and some of the directors are common in both entities. The promoter(s), promoter group or group companies have interest in the entity being acquired. The transaction is being undertaken pursuant to the terms and conditions of the BLPL SSA executed between the parties and is on an arm's length basis.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of further shares of BLPL is made with an objective to strengthen the operational efficiency, long-term competitiveness, achieve strategic

		synergies, and enhance long-term shareholder value.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	In principle, listing and trading approval of the stock exchanges shall be required for listing of the shares to be issued pursuant to preferential issue
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain customary closing conditions under the BLPL SSA and is expected to be completed within 90 days from the date of signing of the BLPL SSA or by such other timelines as may be mutually agreed between the parties.
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The acquisition is proposed to be effected through a share swap agreement, pursuant to which equity shares of the Company shall be allotted to the shareholders of BLPL, in consideration for acquisition of their equity shares held in BLPL, subject to applicable laws and approvals. No cash consideration is expected to be payable.
8	Cost of acquisition and/or the price at which the shares are acquired;	The consideration shall be discharged by issuance of equity shares of the Company in accordance with the agreed share exchange ratio/ swap ratio. The aggregate consideration is approximately Rs.367,840,000/-, subject to customary adjustments, if any. <u>Cost of acquisition</u>: Rs.367,840,000/- <u>Price at which shares are acquired</u>: Up to 22,99,000 equity shares at price of Rs.160/- each aggregating Rs.367,840,000/-.
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<u>Percentage of shareholding acquired</u>: The Company expects to acquire up to 47.41% shareholding in BLPL, subject to acceptance of

<table>
<tr><td></td><td></td><td>share swap proposal by all the shareholders of BLPL.

Control acquired: Not applicable pursuant to the proposed transaction.

Number of shares acquired: Up to 22,99,000 equity shares of the Target Company</td></tr>
<tr><td>10</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</td><td>Brief background: Please refer (1) above.

Country in which the acquired entity has presence: India

Turnover for the last 3 years:

<table><tr><td>Financial Year</td><td>Amt. in Lakh</td></tr><tr><td>2023-24</td><td>Rs.380.39</td></tr><tr><td>2024-25</td><td>Rs.3,038.20</td></tr><tr><td>2025-26</td><td>Rs.3,126.64</td></tr></table></td></tr>
</table>

ANNEXURE - C

Details required under Regulation 30 of SEBI Listing Regulations read with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

The details relating to the issuance of fully paid-up equity shares on a Preferential Basis as required under Regulation 30 of SEBI Listing Regulations are as follows:

<table>
<tr><th>Sr. No.</th><th>Particulars</th><th>Issue of Equity Shares of the Company for consideration other than cash (Share Swap)</th></tr>
<tr><td>1</td><td>Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)</td><td>Equity Shares of face value Rs.02/- (Rupees Two Only) per share.</td></tr>
<tr><td>2</td><td>Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placements, preferential allotment etc.)</td><td>Preferential Allotment for consideration other than cash (swap shares)</td></tr>
<tr><td>3</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)</td><td>Subject to necessary approvals, up to 8,58,83,617 (Eight Crore Fifty-Eight Lakh Eighty-Three Thousand Six-Hundred Seventeen) Equity Shares shall be issued to the identified shareholders of Apiqo Organics Private Limited ("AOPL") and Bizotic Lifescience Private Limited ("BLPL") in accordance with the share exchange ratio of [1:14.45] (for AOPL) and [1:8.96] (for BLPL).

Any fractional entitlement arising pursuant to the swap ratio shall be rounded off to the nearest whole equity share, regardless of the decimal value.</td></tr>
<tr><td>4</td><td colspan="2">In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):</td></tr>
<tr><td>a.</td><td>Name and Number of the Investors</td><td>Name and number of investors in AOPL: Up to 160, as set out below:
<table>
<tr><th>Sr.</th><th>Name of Shareholders</th></tr>
<tr><td>1</td><td>Punitkumar Rameshbhai Rasadia</td></tr>
<tr><td>2</td><td>Meet Atulkumar Vachhani</td></tr>
<tr><td>3</td><td>Other 158 shareholders, who may accept or reject the proposal of share swap.</td></tr>
</table>
Name and number of investors in BLPL: Up to 173, as set out below:
<table>
<tr><th>Sr.</th><th>Name of Shareholders</th></tr>
<tr><td>1</td><td>Punitkumar Rameshbhai Rasadia</td></tr>
<tr><td>2</td><td>Meet Atulkumar Vachhani</td></tr>
</table>
</td></tr>
</table>

ANLON HEALTHCARE LIMITED
CIN No.: U24230GJ2013PLC077543
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)
PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

<table>
<tr><td></td><td></td><td><table><tr><td>3</td><td>Other 171 shareholders, who may accept or reject the proposal of share swap.</td></tr></table></td></tr>
<tr><td>b.</td><td>Post allotment of securities – outcome of the subscription

(in case of AOPL)</td><td>Subject to necessary approvals, the Equity Shares are proposed to be allotted to the investors of AOPL named above. Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under:

<table>
<tr><th>Name of the Shareholders</th><th>Pre-preferential Holding (No. of Share)</th><th>Post-allotment of preferential issue/ share swap Holding in AOPL (No. of Share)</th></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,34,43,043</td></tr>
<tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>10,25,34,740</td></tr>
<tr><td>Other 158 shareholders, who may accept or reject the proposal of share swap.</td><td colspan="2">Not ascertainable as these shareholders may either accept or reject the proposal of share swap.</td></tr>
</table>
* Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under assuming full acceptance of the share by the shareholders of AOPL and BLPL:
<table>
<tr><th>Name of the Shareholders</th><th>Pre-preferential Holding (No. of Share)</th><th>Post-allotment of preferential issue/ share swap Holding</th></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,43,39,402</td></tr>
<tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>10,34,31,099</td></tr>
<tr><td>Other 171 shareholders, who may</td><td colspan="2">Not ascertainable as these shareholders may either</td></tr>
</table></td></tr>
</table>

<table>
<tr><td></td><td></td><td><table><tr><td>accept or reject the proposal of share swap.</td><td>accept or reject the proposal of share swap.</td></tr></table></td></tr>
<tr><td>C</td><td>Post allotment of securities – outcome of the subscription

(in case of BLPL)</td><td>Subject to necessary approvals, the Equity Shares are proposed to be allotted to the investors name above. Details of the shareholding in the Company, prior to and after the preferential issue, are as under:

<table>
<tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding in BLPL (No. of Share)</td></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>18,68,16,359</td></tr>
<tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>9,49,76,359</td></tr>
<tr><td>Other 171 shareholders, who may accept or reject the proposal of share swap.</td><td colspan="2">Not ascertainable as these shareholders may either accept or reject the proposal of share swap.</td></tr>
</table>

* Details of the shareholding in the Company, prior to and after the preferential allotment for consideration other than cash, are as under assuming full acceptance of the share by the shareholders of AOPL and BLPL:
<table>
<tr><td>Name of the Shareholders</td><td>Pre-preferential Holding (No. of Share)</td><td>Post-allotment of preferential issue/ share swap Holding</td></tr>
<tr><td>Punitkumar Rameshbhai Rasadia</td><td>18,59,20,000</td><td>20,43,39,402</td></tr>
<tr><td>Meet Atulkumar Vachhani</td><td>9,40,80,000</td><td>10,34,31,099</td></tr>
<tr><td>Other 171 shareholders, who may</td><td colspan="2">Not ascertainable as these shareholders may either</td></tr>
</table></td></tr>
</table>

anlon

		accept or reject the proposal of share swap.	accept or reject the proposal of share swap.
d.	Issue Price	Rs.17.85/- (Rupees Seventeen Point Eighty-Five Only) per equity share	
f.	In case of convertible intimation on the conversion of securities or on lapse of the tenure of the instrument	Not Applicable	